TY - JOUR
T1 - Improving health outcomes of people with diabetes
T2 - target setting for the WHO Global Diabetes Compact
AU - in collaboration with the Global Health and Population Project on Access to Care for Cardiometabolic Diseases
AU - Gregg, Edward W.
AU - Buckley, James
AU - Ali, Mohammed K.
AU - Davies, Justine
AU - Flood, David
AU - Mehta, Roopa
AU - Griffiths, Ben
AU - Lim, Lee Ling
AU - Manne-Goehler, Jennifer
AU - Pearson-Stuttard, Jonathan
AU - Tandon, Nikhil
AU - Roglic, Gojka
AU - Slama, Slim
AU - Shaw, Jonathan E.
AU - Agoudavi, Kokou
AU - Aryal, Krishna K.
AU - Atun, Rifat
AU - Bahendeka, Silver
AU - Bicaba, Brice Wilfried
AU - Bovet, Pascal
AU - Brian, Garry
AU - Damasceno, Albertino
AU - Davies, Justine I.
AU - Dorobantu, Maria
AU - Farzadfar, Farshad
AU - Geldsetzer, Pascal
AU - Gurung, Mongal Singh
AU - Guwatudde, David
AU - Houehanou, Corine
AU - Houinato, Dismand
AU - Hwalla, Nahla
AU - Jaacks, Lindsay
AU - Karki, Bahadur Khem
AU - Labadarios, Demetre
AU - Lunet, Nuno
AU - Marcus, Maja E.
AU - Martins, Joao
AU - Mayige, Theodory Mary
AU - Norov, Bolormaa
AU - Saeedi Moghaddam, Sahar
AU - Quesnel-Crooks, Sarah
AU - Sibai, Abla M.
AU - Sturua, Lela
AU - Theilmann, Michaela
AU - Tsabedze, Lindiwe
AU - Vollmer, Sebastian
AU - Zhumadilov, Zhaxybay
N1 - Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/4/15
Y1 - 2023/4/15
N2 - The Global Diabetes Compact is a WHO-driven initiative uniting stakeholders around goals of reducing diabetes risk and ensuring that people with diabetes have equitable access to comprehensive, affordable care and prevention. In this report we describe the development and scientific basis for key health metrics, coverage, and treatment targets accompanying the Compact. We considered metrics across four domains: factors at a structural, system, or policy level; processes of care; behaviours and biomarkers such as glycated haemoglobin (HbA1c); and health events and outcomes; and three risk tiers (diagnosed diabetes, high risk, or whole population), and reviewed and prioritised them according to their health importance, modifiability, data availability, and global inequality. We reviewed the global distribution of each metric to set targets for future attainment. This process led to five core national metrics and target levels for UN member states: (1) of all people with diabetes, at least 80% have been clinically diagnosed; and, for people with diagnosed diabetes, (2) 80% have HbA1c concentrations below 8·0% (63·9 mmol/mol); (3) 80% have blood pressure lower than 140/90 mm Hg; (4) at least 60% of people 40 years or older are receiving therapy with statins; and (5) each person with type 1 diabetes has continuous access to insulin, blood glucose meters, and test strips. We also propose several complementary metrics that currently have limited global coverage, but warrant scale-up in population-based surveillance systems. These include estimation of cause-specific mortality, and incidence of end-stage kidney disease, lower-extremity amputations, and incidence of diabetes. Primary prevention of diabetes and integrated care to prevent long-term complications remain important areas for the development of new metrics and targets. These metrics and targets are intended to drive multisectoral action applied to individuals, health systems, policies, and national health-care access to achieve the goals of the Global Diabetes Compact. Although ambitious, their achievement can result in broad health benefits for people with diabetes.
AB - The Global Diabetes Compact is a WHO-driven initiative uniting stakeholders around goals of reducing diabetes risk and ensuring that people with diabetes have equitable access to comprehensive, affordable care and prevention. In this report we describe the development and scientific basis for key health metrics, coverage, and treatment targets accompanying the Compact. We considered metrics across four domains: factors at a structural, system, or policy level; processes of care; behaviours and biomarkers such as glycated haemoglobin (HbA1c); and health events and outcomes; and three risk tiers (diagnosed diabetes, high risk, or whole population), and reviewed and prioritised them according to their health importance, modifiability, data availability, and global inequality. We reviewed the global distribution of each metric to set targets for future attainment. This process led to five core national metrics and target levels for UN member states: (1) of all people with diabetes, at least 80% have been clinically diagnosed; and, for people with diagnosed diabetes, (2) 80% have HbA1c concentrations below 8·0% (63·9 mmol/mol); (3) 80% have blood pressure lower than 140/90 mm Hg; (4) at least 60% of people 40 years or older are receiving therapy with statins; and (5) each person with type 1 diabetes has continuous access to insulin, blood glucose meters, and test strips. We also propose several complementary metrics that currently have limited global coverage, but warrant scale-up in population-based surveillance systems. These include estimation of cause-specific mortality, and incidence of end-stage kidney disease, lower-extremity amputations, and incidence of diabetes. Primary prevention of diabetes and integrated care to prevent long-term complications remain important areas for the development of new metrics and targets. These metrics and targets are intended to drive multisectoral action applied to individuals, health systems, policies, and national health-care access to achieve the goals of the Global Diabetes Compact. Although ambitious, their achievement can result in broad health benefits for people with diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85151491550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151491550&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(23)00001-6
DO - 10.1016/S0140-6736(23)00001-6
M3 - Review article
C2 - 36931289
AN - SCOPUS:85151491550
SN - 0140-6736
VL - 401
SP - 1302
EP - 1312
JO - The Lancet
JF - The Lancet
IS - 10384
ER -